Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology, neurodegeneration, and Immunology. The company's products under development include Elepsia XR for the treatment of epilepsy; PDP-716 for the treatment of open-angle glaucoma; and Sezaby for the treatment of neonatal seizures. In addition, it is developing Vodobatinib (SCC-138), a c-ABL inhibitor, which is in phase 2 clinical trial to treat Parkinson's disease; has completed phase 1 clinical trial for the treatment of lewy body dementia; and in preclinical trial to treat alzheimer's disease. Further, the company develops Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia that is in phase 2 clinical trial; and Vibozilimod (SCD-044), a selective sphingosine-1-phosphate receptor 1 (S1PR1) agonist, for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial. Additionally, it is developing SCD-153 for the treatment of alopecia areata and SBO-154, an anti-MUC-1 ADC, for the treatment of multiple tumors that is in preclinical trials. The company was incorporated in 2006 and is based in Mumbai, India.

Revenue projections:

Revenue projections for SPARC
Revenue projections for SPARC

Sun Pharma Advanced Research Company Limited's projected revenue increase could signal a good investment opportunity if backed by other fundamentals. This growth may appeal to investors seeking a company with improving financial performance and the potential for future profitability, making Sun Pharma Advanced Research Company Limited a potentially rewarding investment option.

Financial Ratios:

currentRatio 0.07000
forwardPE 0.00000
debtToEquity 0.00000
earningsGrowth 0.00000
revenueGrowth 0.64200
grossMargins 0.57919
operatingMargins -1.99946
trailingEps -9.20000
forwardEps 55.40000

Sun Pharma Advanced Research Company Limited's current ratio 0.07 indicates the company may struggle to cover its short-term liabilities with available cash reserves and current assets. This points to potential liquidity challenges, signaling that Sun Pharma Advanced Research Company Limited might need additional funds to meet its near-term obligations.

Price projections:

Price projections for SPARC
Price projections for SPARC